Our Origin Story
“Before co-founding BioLab Holdings I had a long and successful career in the telecommunications industry. At the age of 50, I decided to return to school to get my executive MBA to sharpen my skills and fill any knowledge gaps I had. It proved very impactful, as it allowed me to see other people at different stages in their careers, and what some of them were achieving or not achieving. It made me reflect internally on what I was doing and how I was using my skills.
On my last day of grad school, I had a life-altering moment — a rollover car accident from which I miraculously walked away without a scratch. The next day I was on a plane to Rochester, New York to start a new position and could not help but wonder, “Am I really doing anything to help improve lives or to help others?”. And the answer, painfully, was no. I was helping businesses become more efficient, but I really was not changing lives.
I wanted to create value for other human beings. So, I made a career shift from software sales to regenerative medicine. Yes, it was a big transition, but we are so fortunate today to have a wealth of information at our fingertips. You truly can learn to do anything new you want.
It is been a great journey to where I am now. Regenerative medicine has come a long way in five years, and I think it is going to keep progressing tremendously as we learn more about how the body can help heal itself. This path is enabling me to help people who are suffering from hard-to-heal wounds. We are helping save people’s limbs. We are absolutely changing lives and improving the quality of it for countless individuals. For me, this line of work definitely feels much better than saving a company money or helping a company achieve a better business plan."
Bob Maguire
Chairman of the Board
PR & News
1/27/26
BioLab Holdings Announces Investment in Advanced Synthetic Antimicrobial -Tissue Regeneration Solutions
The partnership allows BioLab to differentiate its skin substitute portfolio, with a focus on the physician office setting, to better align with the varying clinical requirements across the continuum of wound care.
10/29/25
BioLab Holdings Inc. Announces Multiple Clinical Trials to Advance Chronic Wound Care
BioLab Holdings, Inc. a Phoenix-based medical manufacturer specializing in wound care solutions, announced the ongoing development of several clinical trials designed to demonstrate the efficacy and safety of its Cellular, Acellular, and Matrix-like Products (CAMPs) in covering and protecting, non-healing wounds, including diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).
9/4/25
BioLab Holdings, Inc. Announces Strategic Investment in AI Diagnostic Technology
BioLab Holdings, Inc is proud to announce its strategic investment and commercialization partnership with cureVision, a breakthrough digital wound care company using optical sensors, 3D imaging and artificial intelligence, to revolutionize wound analysis and diagnosis.
6/6/25
BioLab keeps data room open for potential buyers as it pursues M&A
BioLab, a manufacturer of regenerative wound-care products, is fielding increasing inbound sale interest as it shops globally for potential buys, said CEO Jaime Leija.
3.25.25
BioLab Holdings, Inc. Announces Medical Advisory Board
Distinguished Wound Care Specialists to Provide Invaluable Insights Across BioLab's Operation
3.07.25
BioLab Holdings, Inc. Announces Partnership with Real Collagen GmbH
Investment and Partnership will Allow Manufacturer to Create New Wound Care Products Using Fish Collagen
01.06.25
BioLab Holdings, Inc. Completes Animal Study on New Wound Care Product
Product Shows Promising Long-Term Results in New Study
2.12.25
BioLab Holdings, Inc. Receives IRB Approval for Trial on Membrane Wrap™
Study will Evaluate Efficacy of Skin Substitute on Venous Leg Ulcers